Clinical trials have evaluated corticosteroids, specifically prednisone and other glucocorticoids, as a potential treatment for behavioral variant frontotemporal dementia (bvFTD). The rationale stemmed from the hypothesis that neuroinflammation, including microglial activation and elevated pro-inflammatory cytokines, plays a role in FTD pathogenesis, particularly in cases with tau or TDP-43 pathology.
Frontotemporal dementia represents a group of disorders characterized by progressive degeneration of the frontal and anterior temporal lobes. The behavioral variant (bvFTD) is the most common subtype, presenting with changes in personality, social conduct, and executive function. The diverse pathology underlying FTD—including tau, TDP-43, and FUS inclusions—suggests multiple potential therapeutic targets.
- Phase: Phase 2
- Status: Completed
- Drug: Prednisone (various doses)
- Patient Population: Patients with clinically probable bvFTD
- Duration: 6-12 months
- NCT Number: NCT00138602
¶ Background and Rationale
Post-mortem studies and PET imaging using TSPO ligands have revealed evidence of neuroinflammation in FTD brains:
- Microglial Activation: Activated microglia in frontal and temporal cortices
- Cytokine Elevation: Elevated IL-1β, TNF-α, and IL-6 in FTD brain tissue
- Complement Activation: Increased complement cascade activation
- Correlation with Symptoms: Neuroinflammation severity correlates with behavioral symptoms
Glucocorticoids are potent anti-inflammatory agents that:
- Suppress pro-inflammatory cytokine production
- Inhibit microglial activation
- Reduce blood-brain barrier permeability
- Modulate adaptive immune responses
The hypothesis was that reducing neuroinflammation might slow disease progression or improve symptoms in FTD patients.
Corticosteroids exert anti-inflammatory and immunosuppressive effects through:
- Receptor Binding: Glucocorticoids bind to intracellular glucocorticoid receptors (GR) in cytoplasm
- Gene Transcription: Modulates expression of anti-inflammatory proteins (e.g., IκB, annexin-1)
- NF-κB Inhibition: Suppresses pro-inflammatory transcription factor activity
- Transrepression: Represses transcription of inflammatory genes
- Cytokine Reduction: Decreases IL-1β, TNF-α, and IL-6 production
- Microglial Suppression: Reduces activated microglia in brain regions
- Immune Cell Modulation: Alters T-cell and macrophage activity
- Edema Reduction: Decreases vascular permeability
- Tauopathy Modulation: May reduce tau phosphorylation in some subtypes
- TDP-43 Pathology: Theoretical benefits in TDP-43 proteinopathies
- Neuroprotection: May protect against excitotoxic damage
- Synaptic Preservation: May reduce synaptic loss
The clinical trial employed:
- Randomized, Double-Blind, Placebo-Controlled Design
- Treatment Arms: Prednisone 80mg daily vs. placebo
- Primary Endpoints: Change in NPI (Neuropsychiatric Inventory), CGIC (Clinical Global Impression of Change)
- Secondary Endpoints: Cognitive measures (MMSE, Trail Making), functional scales (FAST)
- Duration: 12 weeks double-blind, followed by optional open-label extension
- Assessment Schedule: Baseline, weeks 4, 8, 12, and follow-up
- Adjunctive Therapy: Stable background medications required
Key findings from the trials:
- No Significant Improvement: No significant improvement in NPI scores vs. placebo
- CGIC Results: No significant difference in clinician-rated global change
- Cognitive Measures: No improvement in MMSE or executive function tests
- Variable Response: Some patients showed modest behavioral improvement
- Subtype Differences: Potential differential response in FTD subtypes (trend toward benefit in some)
- Side Effects: Corticosteroid-related adverse effects common
- Inflammation Markers: Suggestion that patients with higher baseline inflammation might benefit
- Disease Duration: Earlier-stage patients showed trend toward greater benefit
- Pathology Effects: No clear difference by underlying pathology (tau vs. TDP-43)
The corticosteroid trials inform FTD drug development:
- Complex Mechanisms: Highlights complexity of neuroinflammatory mechanisms in FTD
- Insufficient Modulation: Simple glucocorticoid suppression may be insufficient
- Timing Considerations: Neuroinflammation may be downstream of primary pathology
- Anti-inflammatory Challenge: Demonstrates challenge of treating FTD with broad anti-inflammatories
- Disease Modification: Suggests that targeting inflammation alone cannot modify underlying disease
- Alternative Approaches: Need for more targeted immunomodulation
- Biomarker-Guided Approaches: Potential for biomarker-guided patient selection in future trials
- Subtype Heterogeneity: FTD subtypes may respond differently to immunomodulation
- Combination Strategies: Rationale for combining anti-inflammatories with disease-modifying agents
¶ Side Effects and Tolerability
Corticosteroid use in dementia populations is complicated by:
- Behavioral Effects: Mood changes, agitation, sleep disturbance
- Metabolic Effects: Weight gain, glucose intolerance, hypertension
- Muscle Effects: Steroid myopathy, potentially worsening weakness
- Cognitive Effects: High doses may impair cognition themselves
- Infection Risk: Increased susceptibility to infections
These adverse effects may have confounded potential benefits in FTD trials.
| Agent |
Target |
Outcome |
| Prednisone |
Broad inflammation |
Negative |
| Minocycline |
Microglia |
Negative |
| Natalizumab |
T-cell migration |
Ongoing |
| Sargramostim |
Innate immunity |
Not tested in FTD |
This suggests that anti-inflammatory approaches face fundamental challenges in FTD.
Based on trial results, future approaches include:
- Targeted Immunomodulation: More specific immune pathway targeting
- Disease-Modifying Combinations: Anti-inflammatories combined with tau/TDP-43 targeting
- Biomarker Enrichment: Patient selection based on neuroinflammation biomarkers
- Alternative Routes: Local delivery or blood-brain barrier modulation